Just watching from the outside . It may end up being a huge squeeze up if they have yet another great earnings report but this free fall has me way too nervous to jump aboard at this point.
In April of 2013 XGTI went from about .30 to $9.00 per share and did this on a total of less than 1000 shares, traded on no news at all.
Before that there were only 3 days where any trades at all occurred out of 20 days. Even on those 3 days the totals were in the hundreds.
The stock held that ridiculous move up without any trades at all again for most days. Since then the price sifted lower and lower over 2 years and is back to 30 pennies which IMHO is about .30 more per share than it deserves.
Before you throw your $ away on this do your DD by simply looking at the price history and start your search in April 2013.
You are welcome !
and success can cause 500% increase in share price or much higher yet/ price might get to $90
But 0bviously you're a gambling guy, betting it will fail or why else would you be posting?
You're no investor, you're simply a hypocrite that isn't bright enough not to be seen through.
Nice finish !
and tight usually means - expect some squeezing somewhere along the line
With these results today don't be surprised to see a sweet squeeze sometime today and or tomorrow.
$10.30 on the Earnings report day to $15.10 ...in just 5 days !
Sentiment: Strong Buy
Zacks Investment Research downgraded GlaxoSmithKline plc GSK to a Zacks Rank #5 (Strong Sell) The company has also witnessed sharp downward estimate revisions over the last 30 days..We note that GlaxoSmithKline is under significant pressure because of generic competition faced by its key products.like Valtrex, Imitrex, Requip, Combivir and Epivir are facing declining sales due to intense generic competition. Several other drugs including Epzicom (2016), Lexiva (2018) and Trizivir (2016) and vaccines such as Boostrix (2017) and Infanrix (2016) are also scheduled to lose exclusivity in the next couple of years.
Meanwhile, GlaxoSmithKline has had its share of pipeline setbacks as well including disappointing top-line phase III data on chronic coronary heart disease candidate, darapladib and Duchenne muscular dystrophy candidate, drisapersen, failing to meet the primary endpoint in a phase III study.
Sentiment: Strong Sell
He's a clown, but the uninformed mass adore him. "oh I'd throw this phone but it's not mine" What a load, then obviously he feels the aluminum may not even protect it anyway. And even if every phone in the US had an aluminum case then how much aluminum is that anyway? 10 tons, or 50 tons, total?
A minuscule quantity for a company like AA.
But he knows his clueless followers are just that, clueless, and follow him like he's the Pied Piper . Sad
These guys have been consolidating on low volume after it hit it's high of 15.55 on April 1st, it will uncoil and spring up fast . Today , tommorrow ?
Looks like another one coming later this month